RIPK2 and ovarian serous adenocarcinoma: Overall, our study suggested that RIPK2 could act as a biomarker for Taxol treatment sensitivity in serous ovarian cancer and provides new insights into the mechanisms underlying Taxol resistance in serous ovarian cancer.